We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

55 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 11

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3.12% more ownership

Funds ownership: 78.57% → 81.69% (+3.1%)

2% more funds holding

Funds holding: 54 → 55 (+1)

0% more capital invested

Capital invested by funds: $379M → $379M (+$398K)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.97%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
6
Increased
21
Reduced
11
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$18M
2
BlackRock
BlackRock
New York
+$5.1M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.26M
4
CCM
CAAS Capital Management
New York
+$3.92M
5
Millennium Management
Millennium Management
New York
+$3.29M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$13.2M
2
O
OrbiMed
New York
-$8.26M
3
YU
Yale University
Connecticut
-$2.34M
4
CA
CHI Advisors
New York
-$1.5M
5
Citadel Advisors
Citadel Advisors
Florida
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$48.4M – – –
SI
2
Sofinnova Investments
California
$40.2M – – –
RCM
3
RA Capital Management
Massachusetts
$39.7M – – –
NHAS
4
Novo Holdings A/S
Denmark
$39M -$13.2M -600,000 -23%
DM
5
Deerfield Management
New York
$38.9M +$18M +813,701 +71%
PBPIA
6
Pivotal bioVenture Partners Investment Advisor
California
$31.5M – – –
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$21.6M +$4.26M +193,000 +22%
CA
8
CHI Advisors
New York
$18.4M -$1.5M -68,132 -7%
BlackRock
9
BlackRock
New York
$17.1M +$5.1M +230,932 +37%
RSCM
10
Rock Springs Capital Management
Maryland
$16.4M -$58.4K -2,646 -0.3%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$12.1M – – –
Wellington Management Group
12
Wellington Management Group
Massachusetts
$9.26M +$638K +28,914 +7%
SCM
13
Suvretta Capital Management
New York
$6.76M +$2.8M +127,116 +59%
Vanguard Group
14
Vanguard Group
Pennsylvania
$6.75M +$703K +31,850 +10%
Citadel Advisors
15
Citadel Advisors
Florida
$4.76M -$268K -12,141 -5%
CCM
16
CAAS Capital Management
New York
$3.52M +$3.92M +177,502 New
BCM
17
Burrage Capital Management
Massachusetts
$3.36M -$29.2K -1,323 -0.8%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.98M +$969K +43,915 +41%
Millennium Management
19
Millennium Management
New York
$2.95M +$3.29M +149,205 New
State Street
20
State Street
Massachusetts
$2.62M +$323K +14,640 +12%
Northern Trust
21
Northern Trust
Illinois
$2.29M +$500K +22,663 +24%
BBA
22
Baker Bros. Advisors
New York
$2.12M – – –
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$1.3M +$1.45M +65,781 New
Charles Schwab
24
Charles Schwab
California
$1.18M +$231K +10,450 +21%
Marshall Wace
25
Marshall Wace
United Kingdom
$1.03M +$1.14M +51,813 New
1
2 3

INZY Hedge Fund Activity: Q1 2021 in Review

55 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2021, worth a combined $379M — up 0.11% from $379M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INZY positions and 5 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.

The largest buyer was Deerfield Management, adding an estimated $18M. The largest seller was Novo Holdings A/S, cutting an estimated $13.2M.

  • 55 institutional investors held Inozyme Pharma (INZY) as of Q1 2021, up from 54 in Q4 2020.
  • Funds reported $379M of Inozyme Pharma stock for Q1 2021, up 0.11% quarter-over-quarter.
  • 6 funds opened new Inozyme Pharma positions in Q1 2021 and 5 closed out, a net change of +1 holder.
  • The largest Inozyme Pharma buyer in Q1 2021 was Deerfield Management, an estimated $18M added.
  • The largest Inozyme Pharma seller in Q1 2021 was Novo Holdings A/S, an estimated $13.2M sold.

Based on aggregated 13F filings for Q1 2021.